|
1
|
Ma Z, Cai H and Cui Y: Progress in the
treatment of esophageal neuroendocrine carcinoma. Tumour Biol.
39:10104283177113132017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fraenkel M, Kim MK, Faggiano A and Valk
GD: Epidemiology of gastroenteropancreatic neuroendocrine tumours.
Best Pract Res Clin Gastroenterol. 26:691–703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dasari A, Mehta K, Byers LA, Sorbye H and
Yao JC: Comparative study of lung and extrapulmonary poorly
differentiated neuroendocrine carcinomas: A SEER database analysis
of 162,983 cases. Cancer. 124:807–815. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
IARC Working Group on the Evaluation of
Carcinogenic Risks to Humans, . Drinking Coffee, Mate, and Very Hot
Beverages. International Agency for Research on Cancer; Lyon: pp.
4882018
|
|
5
|
Hirabayashi K, Zamboni G, Nishi T, Tanaka
A, Kajiwara H and Nakamura N: Histopathology of gastrointestinal
neuroendocrine neoplasms. Front Oncol. 3:22013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nevárez A, Saftoiu A and Bhutani MS:
Primary small cell carcinoma of the esophagus: Clinico-
pathological features and therapeutic options. Curr Health Sci J.
37:31–34. 2011.PubMed/NCBI
|
|
7
|
Huang Q, Fang DC, Yu CG, Zhang J and Chen
MH: Barrett's esophagus-related diseases remain uncommon in China.
J Dig Dis. 12:420–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al Mansoor S, Ziske C and Schmidt-Wolf
IGH: Primary small cell carcinoma of the esophagus: Patient data
metaanalysis and review of the literature. Ger Med Sci.
11:Doc122013.PubMed/NCBI
|
|
9
|
Imai T, Sannohe Y and Okano H: Oat cell
carcinoma (apudoma) of the esophagus: A case report. Cancer.
41:358–364. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Giannetta E, Guarnotta V, Rota F, de Cicco
F, Grillo F, Colao A and Faggiano A; NIKE: A rare rarity:
Neuroendocrine tumor of the esophagus. Crit Rev Oncol Hematol.
137:92–107. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu H, Yu Z, Liu Y, Guo L, Teng L, Guo L,
Liang L, Wang J, Gao J, Li R, et al: Genomic characterization
reveals distinct mutation landscapes and therapeutic implications
in neuroendocrine carcinomas of the gastrointestinal tract. Cancer
Commun (Lond). 42:1367–1386. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ji A, Jin R, Zhang R and Li H: Primary
small cell carcinoma of the esophagus: Progression in the last
decade. Ann Transl Med. 8:5022020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gonzalez RS: Diagnosis and management of
gastrointestinal neuroendocrine neoplasms. Surg Pathol Clin.
13:377–397. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takagi K, Kamada T, Fuse Y, Kai W,
Takahashi J, Nakashima K, Nakaseko Y, Suzuki N, Yoshida M, Okada S,
et al: Nivolumab in combination with radiotherapy for metastatic
esophageal neuroendocrine carcinoma after esophagectomy: A case
report. Surg Case Rep. 7:2212021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanzawa S, Asami S, Kanazawa T, Oono S and
Takakura N: Multimodal treatment with nivolumab contributes to
long-term survival in a case of unresectable esophagogastric
junction neuroendocrine carcinoma. Cureus. 16:e659812024.PubMed/NCBI
|
|
16
|
Liu L, Liu Y, Gong L, Zhang M and Wu W:
Salvage camrelizumab plus apatinib for relapsed esophageal
neuroendocrine carcinoma after esophagectomy: A case report and
review of the literature. Cancer Biol Ther. 21:983–989. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Patel SP, Othus M, Chae YK, Giles FJ,
Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, et
al: A phase II basket trial of dual anti-CTLA-4 and Anti-PD-1
blockade in rare tumors (DART SWOG 1609) in patients with
nonpancreatic neuroendocrine tumors. Clin Cancer Res. 26:2290–2296.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Capdevila J, Teule A, López C,
García-Carbonero R, Benavent M, Custodio A, Cubillo A, Alonso V,
Gordoa TA, Carmona-Bayonas A, et al: 1157O A multi-cohort phase II
study of durvalumab plus tremelimumab for the treatment of patients
(pts) with advanced neuroendocrine neoplasms (NENs) of
gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601).
Ann Oncol. 31:S770–S771. 2020. View Article : Google Scholar
|
|
19
|
Zhou L, Xu G, Chen T, Wang Q, Zhao J,
Zhang T, Duan R and Xia Y: Anlotinib plus camrelizumab achieved
long-term survival in a patient with metastatic esophageal
neuroendocrine carcinoma. Cancer Rep (Hoboken).
6:e18552023.PubMed/NCBI
|
|
20
|
Zhang Y, Liu X, Liang H, Liu W, Wang H and
Li T: Late-stage esophageal neuroendocrine carcinoma in a patient
treated with tislelizumab combined with anlotinib: A case report. J
Int Med Res. 51:30006052311879422023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang P, Shi S, Xu J, Chen Z, Song L,
Zhang X, Cheng Y, Zhang Y, Ye F, Li Z, et al: Surufatinib plus
toripalimab in patients with advanced neuroendocrine tumours and
neuroendocrine carcinomas: An open-label, single-arm, multi-cohort
phase II trial. Eur J Cancer. 199:1135392024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Borghesani M, Reni A, Lauricella E, Rossi
A, Moscarda V, Trevisani E, Torresan I, Al-Toubah T, Filoni E,
Luchini C, et al: Efficacy and toxicity analysis of mFOLFIRINOX in
high-grade gastroenteropancreatic neuroendocrine neoplasms. J Natl
Compr Canc Netw. 22:e2470052024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Walter T, Lievre A, Coriat R, Malka D,
Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G,
et al: Bevacizumab plus FOLFIRI after failure of platinum-etoposide
first-line chemotherapy in patients with advanced neuroendocrine
carcinoma (PRODIGE 41-BEVANEC): A randomised, multicentre,
non-comparative, open-label, phase 2 trial. Lancet Oncol.
24:297–306. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eads JR, Catalano PJ, Fisher GA, Rubin D,
Iagaru A, Klimstra DS, Konda B, Kwong MS, Chan JA, de Jesus-Acosta
A, et al: Randomized phase II study of platinum and etoposide (EP)
versus temozolomide and capecitabine (CAPTEM) in patients (pts)
with advanced G3 non-small cell gastroenteropancreatic
neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. J Clin
Oncol. 40 (16_suppl):S40202022. View Article : Google Scholar
|
|
25
|
Morizane C, Machida N, Honma Y, Okusaka T,
Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, et al:
Effectiveness of etoposide and cisplatin vs irinotecan and
cisplatin therapy for patients with advanced neuroendocrine
carcinoma of the digestive system: The TOPIC-nec phase 3 randomized
clinical trial. JAMA Oncol. 8:1447–1455. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weaver JMJ, Hubner RA, Valle JW and
McNamara MG: Selection of chemotherapy in advanced poorly
differentiated extra-pulmonary neuroendocrine carcinoma. Cancers
(Basel). 15:49512023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang L, Sun X, Zou Y and Meng X: Small
cell type neuroendocrine carcinoma colliding with squamous cell
carcinoma at esophagus. Int J Clin Exp Pathol. 7:1792–1795.
2014.PubMed/NCBI
|
|
29
|
Wilson CI, Summerall J, Willis I, Lubin J
and Inchausti BC: Esophageal collision tumor (Large cell
neuroendocrine carcinoma and papillary carcinoma) arising in a
Barrett esophagus. Arch Pathol Lab Med. 124:411–415. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maru DM, Khurana H, Rashid A, Correa AM,
Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG and
Hofstetter WL: Retrospective study of clinicopathologic features
and prognosis of high-grade neuroendocrine carcinoma of the
esophagus. Am J Surg Pathol. 32:1404–1411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Klöppel G: Classification and pathology of
gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat
Cancer. 18 (Suppl 1):S1–S16. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Capelli P, Fassan M and Scarpa A:
Pathology-grading and staging of GEP-NETs. Best Pract Res Clin
Gastroenterol. 26:705–717. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rooper LM, Bishop JA and Westra WH: INSM1
is a sensitive and specific marker of neuroendocrine
differentiation in head and neck tumors. Am J Surg Pathol.
42:665–671. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang D, Zhang GB, Yan L, Wei XE, Zhang YZ
and Li WB: CT and enhanced CT in diagnosis of gastrointestinal
neuroendocrine carcinomas. Abdom Imaging. 37:738–745. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schott M, Klöppel G, Raffel A, Saleh A,
Knoefel WT and Scherbaum WA: Neuroendocrine neoplasms of the
gastrointestinal tract. Dtsch Arztebl Int. 108:305–312.
2011.PubMed/NCBI
|
|
36
|
Islam O, Sarti K, Verbruggen L,
Vandersmissen V, Bulcke KV, Annys L, Verslype C, Van Laethem JL,
Kalantari HR, Janssens J, et al: Management of high-grade
neuroendocrine neoplasms: Impact of functional imaging. Endocr
Relat Cancer. 32:e2402312025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sahani DV, Bonaffini PA, Fernández-Del
Castillo C and Blake MA: Gastroenteropancreatic neuroendocrine
tumors: Role of imaging in diagnosis and management. Radiology.
266:38–61. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Strosberg J, El-Haddad G, Wolin E,
Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H,
et al: Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine
tumors. N Engl J Med. 376:125–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chan DS, Kanagaratnam AL, Pavlakis N and
Chan DL: Peptide receptor chemoradionuclide therapy for
neuroendocrine neoplasms: A systematic review. J Neuroendocrinol.
37:e133552025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017.PubMed/NCBI
|
|
41
|
Lee CG, Lim YJ, Park SJ, Jang BI, Choi SR,
Kim JK, Kim YT, Cho JY, Yang CH, Chun HJ, et al: The clinical
features and treatment modality of esophageal neuroendocrine
tumors: A multicenter study in Korea. BMC Cancer. 14:5692014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fukui H, Dohi O, Miyazaki H, Yasuda T,
Yoshida T, Ishida T, Doi T, Hirose R, Inoue K, Harusato A, et al: A
case of endoscopic submucosal dissection for neuroendocrine
carcinoma of the esophagus with invasion to the muscularis mucosae.
Clin J Gastroenterol. 15:339–344. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng YQ, Wang GF, Zhou XL, Lin M, Zhang
XW and Huang Q: Early adenocarcinoma mixed with a neuroendocrine
carcinoma component arising in the gastroesophageal junction: A
case report. World J Gastrointest Oncol. 16:563–570. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vest M, Shah D, Nassar M and Niknam N:
Neuroendocrine carcinoma of the esophagus with liver metastasis: A
case report. Cureus. 14:e288422022.PubMed/NCBI
|
|
45
|
Honma Y, Nagashima K, Hirano H, Shoji H,
Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, et al:
Clinical outcomes of locally advanced esophageal neuroendocrine
carcinoma treated with chemoradiotherapy. Cancer Med. 9:595–604.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alese OB, Jiang R, Shaib W, Wu C, Akce M,
Behera M and El-Rayes BF: High-grade gastrointestinal
neuroendocrine carcinoma management and outcomes: A national cancer
database study. Oncologist. 24:911–920. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Enjoji T, Kobayashi S, Hayashi K, Tetsuo
H, Matsumoto R, Maruya Y, Araki T, Honda T, Akazawa Y, Kanetaka K,
et al: Long-term survival after conversion surgery for an
esophageal neuroendocrine carcinoma: A case report. Gen Thorac
Cardiovasc Surg Cases. 3:282024.PubMed/NCBI
|
|
48
|
Shapiro J, van Lanschot JJB, Hulshof MCCM,
van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven
HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al:
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for
oesophageal or junctional cancer (CROSS): Long-term results of a
randomised controlled trial. Lancet Oncol. 16:1090–1098. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ito T, Masui T, Komoto I, Doi R, Osamura
RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, et al:
JNETS clinical practice guidelines for gastroenteropancreatic
neuroendocrine neoplasms: diagnosis, treatment, and follow-up: A
synopsis. J Gastroenterol. 56:1033–1044. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kikuchi Y, Shimada H, Yamaguchi K and
Igarashi Y: Systematic review of case reports of Japanese
esophageal neuroendocrine cell carcinoma in the Japanese
literature. Int Cancer Conf J. 8:47–57. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Awada H, Ali AH, Bakhshwin A and Daw H:
High-grade large cell neuroendocrine carcinoma of the esophagus: A
case report and review of the literature. J Med Case Rep.
17:1442023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shah MH, Goldner WS, Benson AB, Bergsland
E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, et
al: Neuroendocrine and adrenal tumors, version 2.2021, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
19:839–868. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wong AT, Shao M, Rineer J, Osborn V,
Schwartz D and Schreiber D: Treatment and survival outcomes of
small cell carcinoma of the esophagus: An analysis of the National
cancer data base. Dis Esophagus. 30:1–5. 2017.
|
|
54
|
Moertel CG, Kvols LK, O'Connell MJ and
Rubin J: Treatment of neuroendocrine carcinomas with combined
etoposide and cisplatin. Evidence of major therapeutic activity in
the anaplastic variants of these neoplasms. Cancer. 68:227–232.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yamaguchi T, Machida N, Morizane C, Kasuga
A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J,
et al: Multicenter retrospective analysis of systemic chemotherapy
for advanced neuroendocrine carcinoma of the digestive system.
Cancer Sci. 105:1176–1181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
McNamara MG, Frizziero M, Jacobs T,
Lamarca A, Hubner RA, Valle JW and Amir E: Second-line treatment in
patients with advanced extra-pulmonary poorly differentiated
neuroendocrine carcinoma: A systematic review and meta-analysis.
Ther Adv Med Oncol. 12:17588359209152992020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ooki A, Osumi H, Fukuda K and Yamaguchi K:
Potent molecular-targeted therapies for gastro-entero-pancreatic
neuroendocrine carcinoma. Cancer Metastasis Rev. 42:1021–1054.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Imai H, Shirota H, Okita A, Komine K,
Saijo K, Takahashi M, Takahashi S, Takahashi M, Shimodaira H and
Ishioka C: Efficacy and safety of carboplatin and etoposide
combination chemotherapy for extrapulmonary neuroendocrine
carcinoma: A retrospective case series. Chemotherapy. 61:111–116.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sorbye H, Welin S, Langer SW, Vestermark
LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K,
et al: Predictive and prognostic factors for treatment and survival
in 305 patients with advanced gastrointestinal neuroendocrine
carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 24:152–160.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chan DL, Bergsland EK, Chan JA, Gadgil R,
Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj
NP, et al: Temozolomide in grade 3 gastroenteropancreatic
neuroendocrine neoplasms: A multicenter retrospective review.
Oncologist. 26:950–955. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Butt BP, Stokmo HL, Ladekarl M, Tabaksblat
EM, Sorbye H, Revheim ME and Hjortland GO: 1108P Folfirinox in the
treatment of advanced gastroenteropancreatic neuroendocrine
carsinomas. ESMO. 32:S9152021.
|
|
62
|
Hentic O, Hammel P, Couvelard A, Rebours
V, Zappa M, Palazzo M, Maire F, Goujon G, Gillet A, Lévy P, et al:
FOLFIRI regimen: An effective second-line chemotherapy after
failure of etoposide-platinum combination in patients with
neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 19:751–757.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sugiyama K, Shiraishi K, Sato M, Nishibori
R, Nozawa K and Kitagawa C: Salvage chemotherapy by folfiri regimen
for poorly differentiated gastrointestinal neuroendocrine
carcinoma. J Gastrointest Cancer. 52:947–951. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hadoux J, Malka D, Planchard D, Scoazec
JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P,
Berdelou A, et al: Post-first-line FOLFOX chemotherapy for grade 3
neuroendocrine carcinoma. Endocr Relat Cancer. 22:289–298. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Merola E, Dal Buono A, Denecke T, Arsenic
R, Pape UF, Jann H, Wiedenmann B and Pavel ME: Efficacy and
toxicity of 5-Fluorouracil-Oxaliplatin in gastroenteropancreatic
neuroendocrine neoplasms. Pancreas. 49:912–917. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Du Z, Wang Y, Zhou Y, Wen F and Li Q:
First-line irinotecan combined with 5-fluorouracil and leucovorin
for high-grade metastatic gastrointestinal neuroendocrine
carcinoma. Tumori. 99:57–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lamarca A, Frizziero M, Barriuso J,
McNamara MG, Hubner RA and Valle JW: Urgent need for consensus:
International survey of clinical practice exploring use of
platinum-etoposide chemotherapy for advanced extra-pulmonary high
grade neuroendocrine carcinoma (EP-G3-NEC). Clin Transl Oncol.
21:950–953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Shah MH, Goldner WS, Benson AB, Bergsland
E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, et
al: Neuroendocrine and adrenal tumors, version 2.2021, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
19:839–868. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Frizziero M, Spada F, Lamarca A, Kordatou
Z, Barriuso J, Nuttall C, McNamara MG, Hubner RA, Mansoor W,
Manoharan P, et al: Carboplatin in combination with oral or
intravenous etoposide for extra-pulmonary, poorly-differentiated
neuroendocrine carcinomas. Neuroendocrinology. 109:100–112. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hadoux J, Walter T, Kanaan C, Hescot S,
Hautefeuille V, Perrier M, Tauveron I, Laboureau S, Do Cao C,
Petorin C, et al: Second-line treatment and prognostic factors in
neuroendocrine carcinoma: the RBNEC study. Endocr Relat Cancer.
29:569–580. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bardasi C, Spallanzani A, Benatti S, Spada
F, Laffi A, Antonuzzo L, Lavacchi D, Marconcini R, Ferrari M,
Rimini M, et al: Irinotecan-based chemotherapy in extrapulmonary
neuroendocrine carcinomas: Survival and safety data from a
multicentric Italian experience. Endocrine. 74:707–713. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
McNamara MG, Swain J, Craig Z, Sharma R,
Faluyi O, Wadsley J, Morgan C, Wall LR, Chau I, Reed N, et al:
NET-02: A randomised, non-comparative, phase II trial of
nal-IRI/5-FU or docetaxel as second-line therapy in patients with
progressive poorly differentiated extra-pulmonary neuroendocrine
carcinoma. EClinicalMedicine. 60:1020152023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Welin S, Sorbye H, Sebjornsen S, Knappskog
S, Busch C and Oberg K: Clinical effect of temozolomide-based
chemotherapy in poorly differentiated endocrine carcinoma after
progression on first-line chemotherapy. Cancer. 117:4617–4622.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kobayashi N, Takeda Y, Okubo N, Suzuki A,
Tokuhisa M, Hiroshima Y and Ichikawa Y: Phase II study of
temozolomide monotherapy in patients with extrapulmonary
neuroendocrine carcinoma. Cancer Sci. 112:1936–1942. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
von Arx C, Della Vittoria Scarpati G,
Cannella L, Clemente O, Marretta AL, Bracigliano A, Picozzi F,
Iervolino D, Granata V, Modica R, et al: A new schedule of one week
on/one week off temozolomide as second-line treatment of advanced
neuroendocrine carcinomas (TENEC-TRIAL): A multicenter, open-label,
single-arm, phase II trial. ESMO Open. 9:1030032024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Bongiovanni A, Liverani C, Foca F, Bergamo
F, Leo S, Pusceddu S, Gelsomino F, Brizzi MP, Di Meglio G, Spada F,
et al: A randomized phase II trial of Captem or Folfiri as
second-line therapy in neuroendocrine carcinomas. Eur J Cancer.
208:1141292024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Chen MH, Chou WC, Hsiao CF, Jiang SS, Tsai
HJ, Liu YC, Hsu C, Shan YS, Hung YP, Hsich CH, et al: An
open-label, single-arm, two-stage, multicenter, phase II study to
evaluate the efficacy of TLC388 and genomic analysis for poorly
differentiated neuroendocrine carcinomas. Oncologist. 25:e782–e788.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Okuyama H, Ikeda M, Okusaka T, Furukawa M,
Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, et
al: A phase II trial of everolimus in patients with advanced
pancreatic neuroendocrine carcinoma refractory or intolerant to
platinum-containing chemotherapy (NECTOR Trial).
Neuroendocrinology. 110:988–993. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Tarhini A, Kotsakis A, Gooding W, Shuai Y,
Petro D, Friedland D, Belani CP, Dacic S and Argiris A: Phase II
study of everolimus (RAD001) in previously treated small cell lung
cancer. Clin Cancer Res. 16:5900–5907. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Levy S, Verbeek WHM, Eskens FALM, van den
Berg JG, de Groot DJA, van Leerdam ME and Tesselaar MET: First-line
everolimus and cisplatin in patients with advanced extrapulmonary
neuroendocrine carcinoma: A nationwide phase 2 single-arm clinical
trial. Ther Adv Med Oncol. 14:175883592210770882022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Christopoulos P, Engel-Riedel W, Grohé C,
Kropf-Sanchen C, von Pawel J, Gütz S, Kollmeier J, Eberhardt W,
Ukena D, Baum V, et al: Everolimus with paclitaxel and carboplatin
as first-line treatment for metastatic large-cell neuroendocrine
lung carcinoma: a multicenter phase II trial. Ann Oncol.
28:1898–1902. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ünal Ç and Sağlam S: Metronomic
Temozolomide (mTMZ) and Bevacizumab-The Safe and Effective Frontier
for Treating Metastatic Neuroendocrine Tumors (NETs): A
Single-Center Experience. Cancers (Basel). 23:56882023. View Article : Google Scholar
|
|
86
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liu SV, Reck M, Mansfield AS, Mok T,
Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J,
Califano R, Nishio M, et al: Updated overall survival and PD-L1
subgroup analysis of patients with extensive-stage small-cell lung
cancer treated with atezolizumab, carboplatin, and etoposide
(IMpower133). J Clin Oncol. 39:619–630. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab plus platinum-etoposide versus platinum-etoposide
in first-line treatment of extensive-stage small-cell lung cancer
(CASPIAN): A randomised, controlled, open-label, phase 3 trial.
Lancet. 394:1929–1939. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Goldman JW, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab, with or without tremelimumab, plus
platinum-etoposide versus platinum-etoposide alone in first-line
treatment of extensive-stage small-cell lung cancer (CASPIAN):
Updated results from a randomised, controlled, open-label, phase 3
trial. Lancet Oncol. 22:51–65. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chan DL, Rodriguez-Freixinos V, Doherty M,
Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A,
et al: Avelumab in unresectable/metastatic, progressive, grade 2–3
neuroendocrine neoplasms (NENs): Combined results from NET-001 and
NET-002 trials. Eur J Cancer. 169:74–81. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Reddy SM, Reuben A and Wargo JA:
Influences of BRAF inhibitors on the immune microenvironment and
the rationale for combined molecular and immune targeted therapy.
Curr Oncol Rep. 18:422016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L,
Han B, Chen G, He J, Wang J, et al: Anlotinib vs placebo as third-
or further-line treatment for patients with small cell lung cancer:
A randomised, double-blind, placebo-controlled Phase 2 study. Br J
Cancer. 125:366–371. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z,
Zhao J, Yu Y, Hu C, Yang K, et al: Tislelizumab plus chemotherapy
vs chemotherapy alone as first-line treatment for advanced squamous
non-small-cell lung cancer: A phase 3 randomized clinical trial.
JAMA Oncol. 7:709–717. 2021. View Article : Google Scholar : PubMed/NCBI
|
